Development of a human neonatal rotavirus vaccine for the revention of rotavirus disease from birth

Project Details

Despite clear evidence of the success of rotavirus vaccines there remain barriers to global implementation. The human neonatal vaccine, RV3-BB, provides the opportunity for a birth dose administration strategy to protect babies from rotavirus disease from birth.  

The RV3-BB vaccine was developed from the novel human neonatal rotavirus strain, RV3 (G3, P[6]), identified from the faeces of asymptomatic infants in Melbourne obstetric hospital nurseries in 1974 to 1983. Natural infection with RV3 provided protection from severe (100%) and moderately severe (75%) rotavirus gastroenteritis during the first 3 years of life with strong heterotypic serological responses to community rotavirus strains. The intrinsic characteristics of the RV3 strain may make RV3-BB an ideal vaccine candidate to target a birth dose administration vaccine strategy for the protection from rotavirus disease from birth.  

This project aims to provide proof of concept for RV3BB vaccine by studying the protective efficacy, immune response and safety of the RV3BB vaccine administered to infants.

Collaborators

  • Universitas Gadjah Madah, Indonesia
  • University of Otago New Zealand
  • Monash University
  • PATH, USA

Funding

  • Bill and Melinda Gates Foundation
  • National Health and Medical Research Council

Research Publications

  • BINES JE, DANCHIN MD, JACKSON P, HANDLEY A, WATTS E,CROWLEY D, LEE K, WEST A, CHEN MY, BARNES GL, JUSTICE F, BUTTERY J, TAYLOR B, KIRKWOOD C.
    Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered in a birth dose or an infnat dose schedule: A randomised, double blind, placebo controlled trial.  Lancet Infectious Diseases 2015; 15 (12):1361-1498.
  • DANCHIN M, KIRKWOOD CD, LEE KJ, BISHOP RF, WATTS E, JUSTICE FA, CLIFFORD V, COWLEY D, BUTTERY JP, BINES JE
    Phase I trial of RV3-BB rotavirus vaccine: A human neonatal rotavirus vaccine. Vaccine 2013; 31(23): 2610-16
  • DANCHIN M, BINES JE
    Defeating Rotavirus? The Global Recommendation for Rotavirus Vaccination.
    New England Journal of Medicine 2009; 361(20):1919-21
  • YEN C, HEALY K, TATE JE, PARASHAR UD, BINES JE, NEUZIL K, SANTOSHAM M, STEELE AD.
    Rotavirus Vaccination and intussusception - science, surveillance, and safety: a review of evidence and recommendations for future research priorities. Human Vaccines and Immunotherapeutics (in press) (PMID:27322835)
  • CARLIN JB, MACARTNEY KK, LEE KJ, QUINN HE, BUTTERY J, BINES J, MCINTYRE PB
    Intussusception Risk and Disease Prevention Associated with Rotavirus Vaccines in Australia’s National Immunization Program. Clinical Infectious Diseases 2013; 57(10): 1427-34.

Research Group

Rotavirus Group and Enteric Virus Group



Faculty Research Themes

Infection and Immunology



Key Contact

For further information about this research, please contact the research group leader.

Department / Centre

Paediatrics

Unit / Centre

Rotavirus Group and Enteric Virus Group